170 related articles for article (PubMed ID: 10395490)
21. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
[TBL] [Abstract][Full Text] [Related]
22. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
Springer CJ; Niculescu-Duvaz I
Anticancer Drug Des; 1995 Jul; 10(5):361-72. PubMed ID: 7639927
[TBL] [Abstract][Full Text] [Related]
23. Prodrugs of thymidylate synthase inhibitors: potential for antibody directed enzyme prodrug therapy (ADEPT).
Springer CJ; Bavetsias V; Jackman AL; Boyle FT; Marshall D; Pedley RB; Bisset GM
Anticancer Drug Des; 1996 Dec; 11(8):625-36. PubMed ID: 9022750
[TBL] [Abstract][Full Text] [Related]
24. Cellular glutathione as a determinant of the sensitivity of colorectal tumour cell-lines to ZD2767 antibody-directed enzyme prodrug therapy (ADEPT).
Monks NR; Calvete JA; Curtin NJ; Blakey DC; East SJ; Newell DR
Br J Cancer; 2000 Jul; 83(2):267-9. PubMed ID: 10901381
[TBL] [Abstract][Full Text] [Related]
25. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination.
Marais R; Spooner RA; Light Y; Martin J; Springer CJ
Cancer Res; 1996 Oct; 56(20):4735-42. PubMed ID: 8840992
[TBL] [Abstract][Full Text] [Related]
26. Development of triazene prodrugs for ADEPT strategy: new insights into drug delivery system based on carboxypeptidase G2 activation.
Capucha V; Mendes E; Francisco AP; Perry MJ
Bioorg Med Chem Lett; 2012 Nov; 22(22):6903-8. PubMed ID: 23041157
[TBL] [Abstract][Full Text] [Related]
27. Development of dual-acting prodrugs for circumventing multidrug resistance.
Abu Ajaj K; Kratz F
Bioorg Med Chem Lett; 2009 Feb; 19(3):995-1000. PubMed ID: 19131246
[TBL] [Abstract][Full Text] [Related]
28. Application of the ADEPT strategy to the MDR resistance in cancer chemotherapy.
Desbene S; Van HD; Michel S; Tillequin F; Koch M; Schmidt F; Florent JC; Monneret C; Straub R; Czech J; Gerken M; Bosslet K
Anticancer Drug Des; 1999 Apr; 14(2):93-106. PubMed ID: 10405636
[TBL] [Abstract][Full Text] [Related]
29. Suicide gene therapy using E. coli beta-galactosidase.
Farquhar D; Pan BF; Sakurai M; Ghosh A; Mullen CA; Nelson JA
Cancer Chemother Pharmacol; 2002 Jul; 50(1):65-70. PubMed ID: 12111114
[TBL] [Abstract][Full Text] [Related]
30. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
[TBL] [Abstract][Full Text] [Related]
31. Nitroarylmethylcarbamate prodrugs of doxorubicin for use with nitroreductase gene-directed enzyme prodrug therapy.
Hay MP; Wilson WR; Denny WA
Bioorg Med Chem; 2005 Jun; 13(12):4043-55. PubMed ID: 15911317
[TBL] [Abstract][Full Text] [Related]
32. Cationic polymeric gene delivery of beta-glucuronidase for doxorubicin prodrug therapy.
Fonseca MJ; Storm G; Hennink WE; Gerritsen WR; Haisma HJ
J Gene Med; 1999; 1(6):407-14. PubMed ID: 10753066
[TBL] [Abstract][Full Text] [Related]
33. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185.
Eccles SA; Court WJ; Box GA; Dean CJ; Melton RG; Springer CJ
Cancer Res; 1994 Oct; 54(19):5171-7. PubMed ID: 7923136
[TBL] [Abstract][Full Text] [Related]
34. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT).
Springer CJ; Dowell R; Burke PJ; Hadley E; Davis DH; Blakey DC; Melton RG; Niculescu-Duvaz I
J Med Chem; 1995 Dec; 38(26):5051-65. PubMed ID: 8544182
[TBL] [Abstract][Full Text] [Related]
35. Coupling of a Novel TIMP3 Peptide to Carboxypeptidase G2 for Pro-Drug Activation at the Tumour Site.
Aldughaim MS; Alsaffar F; Barker MD
Molecules; 2021 Jan; 26(3):. PubMed ID: 33504102
[TBL] [Abstract][Full Text] [Related]
36. Enzymatic activation of second-generation dendritic prodrugs: Conjugation of self-immolative dendrimers with poly(ethylene glycol) via click chemistry.
Gopin A; Ebner S; Attali B; Shabat D
Bioconjug Chem; 2006; 17(6):1432-40. PubMed ID: 17105221
[TBL] [Abstract][Full Text] [Related]
37. Design and synthesis of water-soluble glucuronide derivatives of camptothecin for cancer prodrug monotherapy and antibody-directed enzyme prodrug therapy (ADEPT).
Leu YL; Roffler SR; Chern JW
J Med Chem; 1999 Sep; 42(18):3623-8. PubMed ID: 10479293
[TBL] [Abstract][Full Text] [Related]
38. Intensely cytotoxic anthracycline prodrugs: glucuronides.
Bakina E; Wu Z; Rosenblum M; Farquhar D
J Med Chem; 1997 Dec; 40(25):4013-8. PubMed ID: 9406592
[TBL] [Abstract][Full Text] [Related]
39. Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluorobenzoic acids for antibody-directed enzyme prodrug therapy.
Springer CJ; Niculescu-Duvaz I; Pedley RB
J Med Chem; 1994 Jul; 37(15):2361-70. PubMed ID: 8057284
[TBL] [Abstract][Full Text] [Related]
40. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2.
Springer CJ; Antoniw P; Bagshawe KD; Searle F; Bisset GM; Jarman M
J Med Chem; 1990 Feb; 33(2):677-81. PubMed ID: 2299634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
